# APR-246 in Combination With Azacitidine for TP53 Mutated AML (Acute Myeloid Leukemia) or MDS (Myelodysplastic Syndromes) Following Allogeneic Stem Cell Transplant

> **NCT03931291** · PHASE2 · COMPLETED · sponsor: **Aprea Therapeutics** · enrollment: 33 (actual)

## Conditions studied

- Acute Myeloid Leukemia or Myelodysplastic Syndromes

## Interventions

- **DRUG:** APR-246

## Key facts

- **NCT ID:** NCT03931291
- **Lead sponsor:** Aprea Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-09-16
- **Primary completion:** 2021-08-27
- **Final completion:** 2022-01-14
- **Target enrollment:** 33 (ACTUAL)
- **Last updated:** 2025-03-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03931291

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03931291, "APR-246 in Combination With Azacitidine for TP53 Mutated AML (Acute Myeloid Leukemia) or MDS (Myelodysplastic Syndromes) Following Allogeneic Stem Cell Transplant". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT03931291. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*